Vanda Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) saw some unusual options trading on Wednesday. Stock investors bought 7,001 call options on the stock. This represents an increase of 1,878% compared to the typical volume of 354 call options.

Vanda Pharmaceuticals Stock Up 29.2 %

VNDA stock traded up $1.14 during mid-day trading on Wednesday, reaching $5.05. 50,660,969 shares of the company traded hands, compared to its average volume of 1,769,567. The stock has a market cap of $290.58 million, a price-to-earnings ratio of 109.22 and a beta of 0.76. Vanda Pharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $7.00. The firm's 50 day moving average price is $4.02 and its 200 day moving average price is $4.05.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.05. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. The business had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. On average, analysts anticipate that Vanda Pharmaceuticals will post 0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Hedge funds have recently modified their holdings of the company. Tower Research Capital LLC TRC lifted its position in shares of Vanda Pharmaceuticals by 91.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,538 shares of the biopharmaceutical company's stock worth $36,000 after buying an additional 2,644 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 352.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 5,186 shares during the period. CWM LLC raised its holdings in shares of Vanda Pharmaceuticals by 61.1% in the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 2,732 shares during the period. PNC Financial Services Group Inc. raised its holdings in shares of Vanda Pharmaceuticals by 46.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 2,904 shares during the period. Finally, Lazard Asset Management LLC raised its holdings in shares of Vanda Pharmaceuticals by 263.0% in the 2nd quarter. Lazard Asset Management LLC now owns 9,718 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 7,041 shares during the period. Institutional investors own 88.14% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. StockNews.com upgraded Vanda Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, March 29th. TheStreet downgraded Vanda Pharmaceuticals from a "c-" rating to a "d" rating in a research note on Thursday, February 8th.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.